{"id":"mob015b-vehicle","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MOB015B vehicle is a pharmaceutical formulation component developed by Moberg Pharma to optimize transdermal or topical drug delivery. As a vehicle, it functions as an inert carrier system that improves the bioavailability and skin penetration of active pharmaceutical ingredients, potentially enhancing therapeutic efficacy of topically applied medications.","oneSentence":"MOB015B is a topical vehicle formulation designed to enhance drug delivery and penetration through the skin barrier.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:04.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Topical drug delivery enhancement (specific indication dependent on active ingredient)"}]},"trialDetails":[{"nctId":"NCT05279846","phase":"PHASE3","title":"A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Moberg Pharma AB","startDate":"2022-05-09","conditions":"Onychomycosis","enrollment":350},{"nctId":"NCT06369727","phase":"PHASE1","title":"Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"2017-10-15","conditions":"Erythema","enrollment":250},{"nctId":"NCT06369675","phase":"PHASE1","title":"Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"2017-10-19","conditions":"Erythema","enrollment":45},{"nctId":"NCT02859519","phase":"PHASE3","title":"A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)","status":"COMPLETED","sponsor":"Moberg Pharma AB","startDate":"2016-10","conditions":"Distal Subungual Onychomycosis","enrollment":365}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MOB015B vehicle","genericName":"MOB015B vehicle","companyName":"Moberg Pharma AB","companyId":"moberg-pharma-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MOB015B is a topical vehicle formulation designed to enhance drug delivery and penetration through the skin barrier. Used for Topical drug delivery enhancement (specific indication dependent on active ingredient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}